Johnson & Johnson's (JNJ) better-than-expected Q2 results and raised full-year outlook are seen as "encouraging" versus the current macro environment, RBC Capital analysts said in a Wednesday note.
The drugmaker is also well-positioned to meet or exceed its full-year guidance as its pharmaceutical and medtech businesses continue to grow, the analysts said.
Growth in core drugs such as Darzalex, Tremfya, and Erleada and share gains in medtech, are expected to sustain revenue through year-end, the firm said.
RBC said that the company's innovation pipeline and broad-based execution support long-term confidence in its outlook.
RBC raised its price target to $185 from $181 and maintained an outperform rating on the stock.
Price: 163.01, Change: -1.77, Percent Change: -1.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.